Illumina moved to reinforce its balance sheet and refinance near-term obligations by entering a $1 billion credit facility with Bank of America and simultaneously arranging a $300 million note offering. The credit agreement replaces an earlier facility and provides flexibility through swingline and letters of credit sublimits, with optional increases up to $500 million in additional commitments. The company also plans to use net proceeds from the 4.950% notes due 2029 to repay its 4.650% notes due Sept. 9, 2026. The note offering is expected to close Aug. 17 with multiple underwriting banks involved. For sequencing-platform stakeholders and assay developers, the move is a read-through on Illumina’s continued investment posture and the financing runway supporting instrument and consumables strategy through the end of the decade.